Bradley Hauser - 16 Dec 2021 Form 4 Insider Report for Soliton, Inc.

Reporting relationship: CEO and President, Director
Issuer ticker: N/A
Reported as of: 16 Dec 2021
Net transaction value: $0
SEC form: 4
Accepted by SEC: 17 Dec 2021, 16:08:14 UTC
Next SEC filing: 19 Apr 2023
Source filing: View source filing
Reporting owner signature: /s/ Bradley Hauser

Key filing fact

Bradley Hauser filed Form 4 for Soliton, Inc. on 17 Dec 2021.

Key facts

This page summarizes Bradley Hauser's Form 4 filing for Soliton, Inc..
5 reported transactions and 5 derivative rows are listed below.
Accepted by SEC: 17 Dec 2021, 16:08.

Change

No earlier filing in this sequence is available for direct comparison.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SOLY transaction Derivative

Stock option (right to buy)

Disposed to Issuer

Transaction value
Shares: -30,000
Change %: -100%
Price
Shares after: 0
Date: 16 Dec 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,000
Exercise price: $1.75
Footnotes: F1

SOLY transaction Derivative

Stock option (right to buy)

Disposed to Issuer

Transaction value
Shares: -15,000
Change %: -100%
Price
Shares after: 0
Date: 16 Dec 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,000
Exercise price: $14.62
Footnotes: F1

SOLY transaction Derivative

Stock option (right to buy)

Disposed to Issuer

Transaction value
Shares: -15,000
Change %: -100%
Price
Shares after: 0
Date: 16 Dec 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 15,000
Exercise price: $12.94
Footnotes: F1

SOLY transaction Derivative

Stock option (right to buy)

Disposed to Issuer

Transaction value
Shares: -350,000
Change %: -100%
Price
Shares after: 0
Date: 16 Dec 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 350,000
Exercise price: $7.16
Footnotes: F1

SOLY transaction Derivative

Restricted Stock Units

Disposed to Issuer

Transaction value
Shares: -200,000
Change %: -100%
Price
Shares after: 0
Date: 16 Dec 2021
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 200,000
Exercise price
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Pursuant to the Agreement and Plan of Merger, dated as of May 8, 2021 (the "Merger Agreement"), by and among Soliton, Inc. (the "Company"), AbbVie Inc. ("AbbVie") and Scout Merger Sub, Inc., a wholly owned subsidiary of AbbVie ("Merger Sub"), immediately prior to the effective time of the merger of Merger Sub with and into the Company (the "Merger"), each outstanding and unexercised option, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to $22.60 (the "Merger Consideration") minus the exercise price that would be due in cash upon exercise of such option.

Footnote F2

Pursuant to the Merger Agreement, immediately prior to the effective time of the Merger, each outstanding restricted stock unit, whether vested or unvested, was converted into the right to receive a cash payment, without interest and subject to deduction for any required withholding under applicable law, in an amount equal to the Merger Consideration.